Potent and selective pyrazole-based inhibitors of B-Raf kinase.
Hansen, J.D., Grina, J., Newhouse, B., Welch, M., Topalov, G., Littman, N., Callejo, M., Gloor, S., Martinson, M., Laird, E., Brandhuber, B.J., Vigers, G., Morales, T., Woessner, R., Randolph, N., Lyssikatos, J., Olivero, A.(2008) Bioorg Med Chem Lett 18: 4692-4695
- PubMed: 18676143 
- DOI: https://doi.org/10.1016/j.bmcl.2008.07.002
- Primary Citation of Related Structures:  
3D4Q - PubMed Abstract: 
Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated the ability to inhibit downstream ERK phosphorylation in LOX tumors from mouse xenograft studies.
Organizational Affiliation: 
Lead Optimization, Array BioPharma, 3200 Walnut Street, Boulder, CO 80301, USA. josh.hansen@arraybiopharma.com